Medfinder
Back to blog

Updated: January 11, 2026

What Is Rinvoq XR? Uses, Dosage, and What You Need to Know in 2026

Author

Peter Daggett

Peter Daggett

Large medication capsule with information icon and educational elements

Rinvoq XR (upadacitinib) treats nine inflammatory conditions from RA to Crohn's disease. Here's everything you need to know about this JAK inhibitor in 2026.

Rinvoq XR (upadacitinib) is a prescription oral medication used to treat a broad range of chronic inflammatory and autoimmune conditions. Since its FDA approval in 2019, it has expanded from a single rheumatoid arthritis indication to nine approved uses spanning rheumatology, dermatology, and gastroenterology — making it one of the most versatile targeted therapies available. Here's everything patients need to know.

What Is Rinvoq XR?

Rinvoq XR is the brand name for upadacitinib extended-release tablets, manufactured by AbbVie. It belongs to a class of drugs called Janus kinase (JAK) inhibitors — specifically, it is a second-generation selective JAK1 inhibitor. Unlike older pan-JAK inhibitors, upadacitinib's selectivity for JAK1 is designed to reduce off-target effects while maintaining strong anti-inflammatory activity.

The drug is available as extended-release tablets in three strengths: 15 mg, 30 mg, and 45 mg. It is taken once daily by mouth, with or without food. (Note: Rinvoq LQ is a separate oral solution formulation used for pediatric patients and is not interchangeable with the tablets.)

What Conditions Does Rinvoq XR Treat?

As of 2026, Rinvoq XR has nine FDA-approved indications:

Rheumatoid Arthritis (RA) — moderate-to-severe, after inadequate response or intolerance to ≥1 TNF blocker (adults)

Psoriatic Arthritis (PsA) — active, after inadequate response or intolerance to ≥1 TNF blocker (adults and children ≥2 years)

Atopic Dermatitis (AD) — refractory moderate-to-severe, when other systemic therapies including biologics are inadequate or inadvisable (adults and children ≥12 years)

Ulcerative Colitis (UC) — moderately-to-severely active (adults)

Crohn's Disease (CD) — moderately-to-severely active (adults); first oral medication approved for Crohn's

Ankylosing Spondylitis (AS) — active (adults)

Non-Radiographic Axial Spondyloarthritis (nr-axSpA) — active (adults)

Polyarticular Juvenile Idiopathic Arthritis (pJIA) — active, after inadequate response or intolerance to ≥1 TNF blocker (patients ≥2 years)

Giant Cell Arteritis (GCA) — FDA approved April 2025; first and only oral JAK inhibitor approved for GCA (adults; 15 mg once daily)

Dosage Guide: How Much Rinvoq XR Do You Take?

Dosage varies by condition. Your doctor will determine the right dose for you. The standard FDA-approved doses are:

RA, PsA, AS, nr-axSpA, GCA, pJIA: 15 mg once daily

Atopic Dermatitis: 15 mg once daily; may increase to 30 mg once daily if response is inadequate

Ulcerative Colitis — Induction: 45 mg once daily for 8 weeks

Ulcerative Colitis — Maintenance: 15 mg or 30 mg once daily

Crohn's Disease — Induction: 45 mg once daily for 12 weeks

Crohn's Disease — Maintenance: 15 mg or 30 mg once daily

How to Take Rinvoq XR

Take once daily, at the same time each day

With or without food — a fatty meal does not significantly affect absorption

Swallow tablet whole — do not cut, crush, or chew

If you miss a dose, take it as soon as you remember the same day; skip if it's the next day

Do not take a double dose to make up for a missed one

Is Rinvoq XR a Biologic?

No. Rinvoq XR is not a biologic. Biologics are large-molecule drugs derived from living cells (like antibodies), given by injection or infusion. Rinvoq XR is a small-molecule oral medication synthesized chemically. It targets JAK enzymes inside cells rather than specific proteins outside cells like biologics do. This distinction matters for insurance — biologics and JAK inhibitors are typically in different benefit categories and have different step therapy requirements.

Who Should NOT Take Rinvoq XR?

Rinvoq XR is contraindicated or not recommended for:

Patients with known hypersensitivity (allergy) to upadacitinib

Pregnant patients (can cause harm to the fetus)

Patients with active serious infections

Patients currently taking other JAK inhibitors or biologic DMARDs

Learn more about side effects and safety: Rinvoq XR Side Effects: What to Expect and When to Call Your Doctor

Need to find Rinvoq XR at a pharmacy near you? Search Medfinder to check real-time inventory at pharmacies in your area.

Frequently Asked Questions

Rinvoq XR (upadacitinib) is used to treat nine conditions: rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, non-radiographic axial spondyloarthritis, polyarticular juvenile idiopathic arthritis, and giant cell arteritis. It's an oral medication taken once daily.

Rinvoq XR is a small-molecule oral medication, not a biologic. It's a JAK inhibitor (specifically a selective JAK1 inhibitor) that works by blocking enzymes inside cells. Biologics are large-molecule drugs derived from living cells, usually given as injections or infusions. This distinction matters for insurance coverage and step therapy requirements.

Yes, for some indications. Rinvoq XR tablets are approved for psoriatic arthritis and polyarticular juvenile idiopathic arthritis in patients 2 years and older, and for atopic dermatitis in patients 12 years and older. Rinvoq LQ (oral solution) is specifically designed for younger pediatric patients with PsA and pJIA and is not interchangeable with the tablets.

The standard FDA-approved dose of Rinvoq XR for rheumatoid arthritis is 15 mg once daily. This is also the standard dose for psoriatic arthritis, ankylosing spondylitis, nr-axSpA, and giant cell arteritis. Higher doses (30 mg or 45 mg) are used in some conditions such as atopic dermatitis (if 15 mg is inadequate) and for induction therapy in UC and Crohn's disease.

Many patients begin to see improvement in symptoms within 2–4 weeks of starting Rinvoq XR, especially for inflammatory conditions like RA and atopic dermatitis. However, full therapeutic benefit may take 8–12 weeks or longer. For UC and Crohn's disease, the induction phase (45 mg for 8–12 weeks) is specifically designed to achieve initial disease control before transitioning to lower maintenance doses.

Medfinder Editorial Standards

Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.

Read our editorial standards

Patients searching for Rinvoq XR also looked for:

Xeljanz (tofacitinib)Olumiant (baricitinib)Humira (adalimumab) / biosimilarsDupixent (dupilumab)Skyrizi (risankizumab)

29,430 have already found their meds with Medfinder.

Start your search today.

29K+
5-star ratingTrusted by 29,430 Happy Patients
      What med are you looking for?
⊙  Find Your Meds
99% success rate
Fast turnaround time
Never call another pharmacy

Need this medication?